Levodopa-Carbidopa
Antiparkinsonian (Dopamine Precursor)- Drug Class
- Antiparkinsonian (Dopamine Precursor)
- Mechanism of Action (MOA)
- Levodopa is converted to dopamine in the CNS; carbidopa blocks peripheral conversion → ↑ central delivery, ↓ peripheral side effects.
- Clinical Notes
- Most effective Parkinson's therapy. Long-term motor fluctuations ('wearing off') and dyskinesias; orthostasis, hallucinations. Don't stop abruptly.
- Source
- FDA label (DailyMed)
Sources
Reviewed June 2026- FDA label (DailyMed) — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Same family
Got a pharmacology lecture that covers Levodopa-Carbidopa? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology